Gut Microbiota, PGx and INSTIs Response

Inclusion will be proposed to: * HIV infected adult patient regularly followed at Centre de reference HIV of CUSL and currently treated by 50mg OD of DTG (n=80) or 50mg OD of BIC (n=30). * Virally controlled immunologically functional HIV infected adult patient regularly followed at Centre de reference HIV of CUSL and shifting from another ARV class to a treatment containing 50mg OD of DTG (n=20) or 50mg OD of BIC (n=20). * HIV infected adult patient retrospectively identified as having stopped standard dosage of DTG (ie. 50mg OD) due to NPAE (insomnia, depression, anxiety) (n=50). Identification will be based on the interrogation of our prospective clinical database. Exclusion Criteria: * Pregnancy at the time of inclusion or expected pregnancy within 12 months, for patients treated by DTG or BIC during the study * Liver failure (Child-Pugh A, B or C)